HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript

NRX Pharmaceuticals (NASDAQ:NRXP) released second-quarter financial results and hosted an earnings c

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.44) per share which missed the an

Key recent and second quarter highlights include: Completed first-cycle FDA review of the Company's

NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.18 per share versus the Zacks

NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plan

NRx Pharmaceuticals NASDAQ: NRXP said it has completed the first-cycle U.S. Food and Drug Administra

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a cl

MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceutic

BTIG analyst Thomas Shrader maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the

No major deficiencies related to the drug product, ingredients, proposed labeling, Chemistry, Manufa

FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed lab

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx" or the "Company") today issued the fo

WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”

First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and S

First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and S

SAN DIEGO--(BUSINESS WIRE)--Kadima Neuropsychiatry Institute and its founder, Dr. David Feifel, have

SARASOTA, Fla, and BOSTON, June 23, 2026 /PRNewswire/ -- ZETA SURGICAL and HOPE Therapeutics, an NRx

D-Cycloserine (DCS) has been reported to augment the effect of Transcranial Magnetic Stimulation (TM

WILMINGTON, Del., June 22, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biop

MIAMI, June 05, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:NRXP, “the Company”) announces

Offering was led by B Group Capital with significant participation from, among others, Columbia Thre

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a

WILMINGTON, Del., June 03, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx P

Tetra Technologies Inc. (NYSE: TTI) shares fell 15.06% in pre-market trading after announcing a $100

NRXP stock fell after hours after NRx Pharmaceuticals announced a public stock offering to raise cap

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a

WILMINGTON, Del., June 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx P

EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure

EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure

Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to

Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, se

NRx Pharmaceuticals (NRXP) is downgraded from 'Buy' to 'Sell' following failures in ZYESAMI and NRX-

Key highlights from the first quarter of operations under the expanded management team include the f

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.04) per share. This is a 88.24 pe

NRx Pharma (NRXP) set to release Q1 earnings on May 18. Analysts expect $19.43 million in revenue, w

Preliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial M

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a biopharmaceutical company that focuses on neuroplastic th

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP)

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and

In the Order, the President notes that, "It is the policy of my Administration to accelerate inn

NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on l

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly earnings of $0.20 per share. This is a 125.97 p